The patent provides composition-of matter protection for BI-1808 and the use of the antibody for the treatment of cancer.

“We are developing the next generation of immuno-oncology cancer treatments and the granting of this patent for BI-1808 is an important milestone in ensuring we robustly protect our innovative products. BI-1808 has already demonstrated encouraging signals of efficacy in the ongoing clinical evaluation in solid tumors and we look forward to progressing the antibody in clinical development," said Martin Welschof, Chief Executive Officer of BioInvent. "We place great value on the protection of our intellectual property as an intrinsic part of the development of our unique cancer immunotherapy pipeline and our overall business strategy."

About BI-1808
BI-1808 could represent a new class of immunomodulatory agent with the potential to improve efficacy of cancer therapy. It is being studied as both a single agent and in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors or T-cell lymphomas, including CTCL. The Phase 2a single agent part is in the dose expansion phase testing the activity in four different tumor types: ovarian cancer (OC), melanoma, non-small cell lung cancer (NSCLC) and other tumor types (e.g. gastrointestinal stromal tumors (GIST)), and TCL/CTCL. The ongoing Phase 1 combination part is in the final stage of the dose escalation phase.

Initial efficacy and safety data from the ongoing Phase 1/2a study show so far:

• One complete response (CR), one partial response (PR) that is still improving, and nine patients with stable disease (SD) of 26 evaluable patients in the single agent arm of BI-1808
• Promising signs of efficacy and favorable safety profile in the Phase 1 dose escalation part studying BI-1808 in combination with KEYTRUDA® (pembrolizumab)

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on the social media platform X: @BioInvent.

For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.